Debevoise & Plimpton LLP is advising Carlyle (NASDAQ: CG), in collaboration with its life sciences franchise Abingworth and their recently formed development company Launch Therapeutics (Launch Tx), in its investment of up to $170 million in biopharmaceutical company Opthea Limited (ASX:OPT; NASDAQ: OPT). For more information, please see the company’s press release.

Opthea is a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases.

The Debevoise team is led by M&A counsel David Iozzi and includes partners Jennifer Chu and Kevin Rinker, and tax partner Peter Schuur and associate Robert Nelson-Sullivan.